JP2010514817A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010514817A5 JP2010514817A5 JP2009544404A JP2009544404A JP2010514817A5 JP 2010514817 A5 JP2010514817 A5 JP 2010514817A5 JP 2009544404 A JP2009544404 A JP 2009544404A JP 2009544404 A JP2009544404 A JP 2009544404A JP 2010514817 A5 JP2010514817 A5 JP 2010514817A5
- Authority
- JP
- Japan
- Prior art keywords
- saccharide
- protein carrier
- protein
- aliquot
- carbodiimide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004169 proteins and genes Human genes 0.000 claims 22
- 108090000623 proteins and genes Proteins 0.000 claims 22
- 150000001720 carbohydrates Chemical class 0.000 claims 19
- 238000000034 method Methods 0.000 claims 18
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 17
- 150000001718 carbodiimides Chemical class 0.000 claims 12
- 125000003277 amino group Chemical group 0.000 claims 9
- 230000021615 conjugation Effects 0.000 claims 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 8
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical group CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims 6
- 230000002163 immunogen Effects 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 4
- 229960005486 vaccine Drugs 0.000 claims 3
- 102000005416 ATP-Binding Cassette Transporters Human genes 0.000 claims 2
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 claims 2
- 101710092462 Alpha-hemolysin Proteins 0.000 claims 2
- 101710197219 Alpha-toxin Proteins 0.000 claims 2
- -1 MRPII Proteins 0.000 claims 2
- 101710124951 Phospholipase C Proteins 0.000 claims 2
- 240000005499 Sasa Species 0.000 claims 2
- 239000002776 alpha toxin Substances 0.000 claims 2
- 238000009833 condensation Methods 0.000 claims 2
- 230000005494 condensation Effects 0.000 claims 2
- 230000001268 conjugating effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 101710154607 Azurocidin Proteins 0.000 claims 1
- 102100026189 Beta-galactosidase Human genes 0.000 claims 1
- 102000014914 Carrier Proteins Human genes 0.000 claims 1
- 108010078791 Carrier Proteins Proteins 0.000 claims 1
- 101000822677 Clostridium perfringens (strain 13 / Type A) Small, acid-soluble spore protein 1 Proteins 0.000 claims 1
- 101000822695 Clostridium perfringens (strain 13 / Type A) Small, acid-soluble spore protein C1 Proteins 0.000 claims 1
- 101710105699 D-alanyl-D-alanine carboxypeptidase DacB Proteins 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 101710128530 Fibrinogen-binding protein Proteins 0.000 claims 1
- 101710141457 Histidine-binding periplasmic protein Proteins 0.000 claims 1
- 102000002297 Laminin Receptors Human genes 0.000 claims 1
- 108010000851 Laminin Receptors Proteins 0.000 claims 1
- 102000004882 Lipase Human genes 0.000 claims 1
- 108090001060 Lipase Proteins 0.000 claims 1
- 239000004367 Lipase Substances 0.000 claims 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims 1
- 101710087657 Manganese ABC transporter substrate-binding lipoprotein Proteins 0.000 claims 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims 1
- 101710167890 Penicillin-binding protein 4 Proteins 0.000 claims 1
- 241000404883 Pisa Species 0.000 claims 1
- 101710092628 Probable histidine-binding protein Proteins 0.000 claims 1
- 101000576806 Protobothrops flavoviridis Small serum protein 1 Proteins 0.000 claims 1
- 101000576807 Protobothrops flavoviridis Small serum protein 2 Proteins 0.000 claims 1
- 101710202103 Putative beta-lactamase HcpD Proteins 0.000 claims 1
- 108091030066 RNAIII Proteins 0.000 claims 1
- 108010031318 Vitronectin Proteins 0.000 claims 1
- 102100035140 Vitronectin Human genes 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 108091008324 binding proteins Proteins 0.000 claims 1
- 230000015271 coagulation Effects 0.000 claims 1
- 238000005345 coagulation Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 108010064033 elastin-binding proteins Proteins 0.000 claims 1
- 102000025748 fibrinogen binding proteins Human genes 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 235000019421 lipase Nutrition 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 102220117512 rs886041928 Human genes 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0700136.5A GB0700136D0 (en) | 2007-01-04 | 2007-01-04 | Process for manufacturing vaccines |
| GB0700136.5 | 2007-01-04 | ||
| PCT/EP2008/050011 WO2008081014A2 (en) | 2007-01-04 | 2008-01-02 | Process for manufacturing vaccines |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010514817A JP2010514817A (ja) | 2010-05-06 |
| JP2010514817A5 true JP2010514817A5 (OSRAM) | 2011-02-10 |
| JP5683815B2 JP5683815B2 (ja) | 2015-03-11 |
Family
ID=37801736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009544404A Expired - Fee Related JP5683815B2 (ja) | 2007-01-04 | 2008-01-02 | ワクチンの製造方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8858955B2 (OSRAM) |
| EP (1) | EP2099487B1 (OSRAM) |
| JP (1) | JP5683815B2 (OSRAM) |
| CA (1) | CA2674007A1 (OSRAM) |
| ES (1) | ES2546186T3 (OSRAM) |
| GB (1) | GB0700136D0 (OSRAM) |
| WO (1) | WO2008081014A2 (OSRAM) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DZ3399A1 (fr) * | 2000-06-29 | 2002-01-03 | Smithkline Beecham Biolog | Composition de vaccin polyvalent |
| WO2002020059A2 (en) | 2000-09-01 | 2002-03-14 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Vibrio cholerae o139 conjugate vaccines |
| UA95237C2 (uk) | 2005-06-27 | 2011-07-25 | Ґлаксосмітклайн Байолоджікалз С.А. | Імуногенна композиція |
| US20180221466A9 (en) * | 2006-06-12 | 2018-08-09 | Glaxosmithkline Biologicals S.A. | Use of alpha-toxin for treating and preventing staphylococcus infections |
| EP2666784B1 (en) | 2007-08-31 | 2017-04-05 | University Of Chicago | Methods and compositions related to immunizing against staphylococcal lung diseases and conditions |
| US9181329B2 (en) | 2007-08-31 | 2015-11-10 | The University Of Chicago | Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions |
| WO2010014304A1 (en) | 2008-07-29 | 2010-02-04 | University Of Chicago | Compositions and methods related to staphylococcal bacterium proteins |
| BRPI0923649A2 (pt) * | 2008-12-24 | 2016-01-19 | Netherlands Vaccine Inst | polipeptídeos de pneumolisina (ply) de streptococcus pneumoniae modificados. |
| PL3281947T3 (pl) | 2009-04-03 | 2020-07-27 | The University Of Chicago | Kompozycje i sposoby związane z wariantami białka A (SpA) |
| SG175092A1 (en) | 2009-04-14 | 2011-11-28 | Novartis Ag | Compositions for immunising against staphylococcus aerus |
| JP5931724B2 (ja) * | 2009-06-29 | 2016-06-08 | ジェノセア バイオサイエンシーズ， インコーポレイテッド | ＳｔｒｅｐｔｏｃｏｃｃｕｓＰｎｅｕｍｏｎｉａｅに対するワクチンおよび組成物 |
| BR112012010223A2 (pt) * | 2009-10-30 | 2016-12-06 | Novartis Ag | purificação de staphylococcus aureus tipo 5 e tipo 8 sacarídeos capsulares |
| WO2011075822A1 (en) | 2009-12-22 | 2011-06-30 | Sanofi Pasteur Limited | Immunogenic compositions and related methods |
| SG186290A1 (en) | 2010-07-02 | 2013-01-30 | Univ Chicago | Compositions and methods related to protein a (spa) variants |
| AU2012207089B2 (en) | 2011-01-20 | 2016-04-14 | Children's Medical Center Corporation | Vaccines and compositions against Streptococcus pneumoniae |
| US8945588B2 (en) | 2011-05-06 | 2015-02-03 | The University Of Chicago | Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides |
| HRP20201127T1 (hr) | 2012-04-26 | 2020-11-27 | University Of Chicago | Antigeni stafilokokne koagulaze i metode primjene istih |
| AU2015290575A1 (en) * | 2014-07-18 | 2017-03-02 | Km Biologics Co., Ltd. | Vaccine containing virus-like particles |
| US9815886B2 (en) | 2014-10-28 | 2017-11-14 | Adma Biologics, Inc. | Compositions and methods for the treatment of immunodeficiency |
| US10881723B2 (en) | 2016-01-15 | 2021-01-05 | Km Biologics Co., Ltd. | Vaccine containing immobilized virus particles |
| US11214600B2 (en) * | 2016-02-12 | 2022-01-04 | The University Of Chicago | Compositions and methods related to antibodies that neutralize coagulase activity during Staphylococcus aureus disease |
| PL3506935T3 (pl) | 2016-09-02 | 2024-06-10 | Sanofi Pasteur, Inc. | Szczepionka przeciwko Neisseria meningitidis |
| US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
| ES3024474T3 (en) | 2016-12-30 | 2025-06-04 | Vaxcyte Inc | Polypeptide-antigen conjugates with non-natural amino acids |
| US10259865B2 (en) | 2017-03-15 | 2019-04-16 | Adma Biologics, Inc. | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |
| AU2020273471A1 (en) | 2019-05-14 | 2021-12-23 | The University Of Chicago | Methods and compositions comprising Staphylococcus protein A (SpA) variants |
| CN114929750B (zh) | 2019-09-13 | 2024-11-22 | 芝加哥大学 | 用于治疗葡萄球菌感染的方法和组合物 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0027888B1 (en) | 1979-09-21 | 1986-04-16 | Hitachi, Ltd. | Semiconductor switch |
| DE3040825A1 (de) * | 1980-10-30 | 1982-09-09 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neues tridekapeptid, verfahren zu seiner herstellung und verwendung |
| US4673574A (en) | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
| US4695624A (en) | 1984-05-10 | 1987-09-22 | Merck & Co., Inc. | Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency |
| IT1187753B (it) | 1985-07-05 | 1987-12-23 | Sclavo Spa | Coniugati glicoproteici ad attivita' immunogenica trivalente |
| US5180815A (en) * | 1988-04-13 | 1993-01-19 | Fuji Photo Film Co., Ltd. | Modified protein for carrying hapten |
| JPH0776236B2 (ja) * | 1988-04-13 | 1995-08-16 | 富士写真フイルム株式会社 | 蛋白質修飾物 |
| CA2006700A1 (en) | 1989-01-17 | 1990-07-17 | Antonello Pessi | Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines |
| EP0482068A1 (en) | 1989-07-14 | 1992-04-29 | American Cyanamid Company | Cytokine and hormone carriers for conjugate vaccines |
| IT1237764B (it) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
| DE69113564T2 (de) | 1990-08-13 | 1996-05-30 | American Cyanamid Co | Faser-Hemagglutinin von Bordetella pertussis als Träger für konjugierten Impfstoff. |
| US5153312A (en) | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
| CA2059692C (en) | 1991-01-28 | 2004-11-16 | Peter J. Kniskern | Pneumoccoccal polysaccharide conjugate vaccine |
| ATE245446T1 (de) | 1992-02-11 | 2003-08-15 | Jackson H M Found Military Med | Dualer träger für immunogene konstrukte |
| IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
| IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
| JP3828145B2 (ja) | 1993-09-22 | 2006-10-04 | ヘンリー エム．ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン | 免疫原性構成物の製造のための新規シアン化試薬を使った可溶性炭水化物の活性化方法 |
| ATE241384T1 (de) | 1995-03-22 | 2003-06-15 | Jackson H M Found Military Med | Herstellung von immunogenen konstrukten unter verwendung von löslichen kohlehydraten, die durch organische cyanylierungs-reagenzien aktiviert wurden |
| ATE205724T1 (de) | 1995-06-07 | 2001-10-15 | Smithkline Beecham Biolog | Vakzine mit einem polysaccharide antigen- trägerprotein konjugat und freien trägerprotein |
| WO1998026799A1 (en) | 1996-12-18 | 1998-06-25 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Conjugate vaccine for salmonella paratyphi a |
| GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
| US5965714A (en) * | 1997-10-02 | 1999-10-12 | Connaught Laboratories, Inc. | Method for the covalent attachment of polysaccharides to protein molecules |
| WO1999055715A2 (en) * | 1998-04-28 | 1999-11-04 | Galenica Pharmaceuticals, Inc. | Polysaccharide-antigen conjugates |
| DE122009000054I1 (de) | 1999-03-19 | 2009-12-31 | Glaxosmithkline Biolog Sa | Impfstoff gegen bakterielle antigene |
| EP1165796A2 (en) | 1999-04-09 | 2002-01-02 | Techlab, Inc. | Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines |
| GB0007432D0 (en) | 2000-03-27 | 2000-05-17 | Microbiological Res Authority | Proteins for use as carriers in conjugate vaccines |
| US20030035806A1 (en) | 2001-05-11 | 2003-02-20 | D'ambra Anello J. | Novel meningitis conjugate vaccine |
| GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
| US20030113350A1 (en) * | 2001-09-19 | 2003-06-19 | Fattom Ali I. | Glycoconjugate vaccines for use in immune-compromised populations |
| CA2493977A1 (en) | 2002-08-02 | 2004-02-19 | Glaxosmithkline Biologicals Sa | Vaccine composition comprising lipooligosaccharide with reduced phase variability |
| MXPA05009351A (es) * | 2003-03-07 | 2006-03-08 | Wyeth Corp | Conjugados de polisacarido-proteina portadora adhesina superficial de estafilococo para inmunizacion contra infecciones nosocomiales. |
| AU2005287505A1 (en) * | 2004-09-22 | 2006-03-30 | Biosynexus Incorporated | Staphylococcal immunogenic compositions |
| GB0428394D0 (en) * | 2004-12-24 | 2005-02-02 | Chiron Srl | Saccharide conjugate vaccines |
| UA95237C2 (uk) | 2005-06-27 | 2011-07-25 | Ґлаксосмітклайн Байолоджікалз С.А. | Імуногенна композиція |
| US7491517B2 (en) | 2006-07-19 | 2009-02-17 | Jeeri R Reddy | Method of producing meningococcal meningitis vaccine for Neisseria meningitidis serotypes A,C,Y, and W-135 |
| US7935407B2 (en) * | 2009-02-23 | 2011-05-03 | Tsung-Wei Chen | Decorations |
-
2007
- 2007-01-04 GB GBGB0700136.5A patent/GB0700136D0/en not_active Ceased
-
2008
- 2008-01-02 WO PCT/EP2008/050011 patent/WO2008081014A2/en not_active Ceased
- 2008-01-02 US US12/521,797 patent/US8858955B2/en not_active Expired - Fee Related
- 2008-01-02 CA CA002674007A patent/CA2674007A1/en not_active Abandoned
- 2008-01-02 JP JP2009544404A patent/JP5683815B2/ja not_active Expired - Fee Related
- 2008-01-02 ES ES08707820.0T patent/ES2546186T3/es active Active
- 2008-01-02 EP EP08707820.0A patent/EP2099487B1/en not_active Not-in-force
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010514817A5 (OSRAM) | ||
| RU2402347C2 (ru) | Иммуногенная композиция | |
| Brown et al. | Memory Th1 cells are protective in invasive Staphylococcus aureus infection | |
| Dayan et al. | Staphylococcus aureus: the current state of disease, pathophysiology and strategies for prevention | |
| Proctor | Challenges for a universal Staphylococcus aureus vaccine | |
| Harro et al. | Vaccine development in Staphylococcus aureus: taking the biofilm phenotype into consideration | |
| Vella et al. | Glycoconjugate vaccines: an update | |
| RU2570730C2 (ru) | Стабильные иммуногенные композиции антигенов staphylococcus aureus | |
| Hwang et al. | Enhancing efficacy and stability of an antiheroin vaccine: examination of antinociception, opioid binding profile, and lethality | |
| RU2011151781A (ru) | ИММУНОГЕННЫЕ КОМПОЗИЦИИ АНТИГЕНОВ Staphylococcus aureus | |
| JP2012504660A5 (OSRAM) | ||
| Karauzum et al. | IBT-V02: A multicomponent toxoid vaccine protects against primary and secondary skin infections caused by Staphylococcus aureus | |
| CN101730543B (zh) | 灭活的葡萄球菌全细胞疫苗 | |
| AU2010280740A1 (en) | Immunogenic composition comprising antigenic S. aureus proteins | |
| Lattar et al. | Protein antigens increase the protective efficacy of a capsule-based vaccine against Staphylococcus aureus in a rat model of osteomyelitis | |
| CA2739581A1 (en) | Compositions and methods related to bacterial eap, emp, and/or adsa proteins | |
| Mohamed et al. | Vaccine development to prevent Staphylococcus aureus surgical-site infections | |
| O'Hara et al. | Comparative efficacy of two leading candidate ricin toxin a subunit vaccines in mice | |
| TW202400225A (zh) | 腦膜炎球菌（Ｎｅｉｓｓｅｒｉａ ｍｅｎｉｎｇｉｔｉｄｉｓ）組成物和使用彼之方法 | |
| RU2006140958A (ru) | Иммунизация против менингококков серогруппы y с помощью белков | |
| US20250206810A1 (en) | Treatment of staphylococcus related diseases | |
| García-Lara et al. | Anti-Staphylococcus aureus immunotherapy: current status and prospects | |
| Scendoni et al. | Vaccines as a preventive tool for substance use disorder: A systematic review including a meta-analysis on nicotine vaccines’ immunogenicity | |
| Brown | Success and failure of vaccines against renin–angiotensin system components | |
| WO2025149609A1 (en) | Formulations for staphylococcus aureus vaccine |